Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/rth2.12436 http://scihub22266oqcxt.onion/10.1002/rth2.12436 33043232!7537313!33043232     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Res+Pract+Thromb+Haemost 2020 ; 4 (8): 1262-1268 Nephropedia Template TP {{tp|p=33043232|t=2020. Thromboinflammation response to tocilizumab in COVID-19 |pdf=|usr=}}{{33043232}} gab.com Text Thromboinflammation response to tocilizumab in COVID-19 JO: Res Pract Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=33043232 #FOAvip BACKGROUND: Coronavirus disease-19 (COVID-19) spans a wide spectrum of illness. Severe cases of COVID-19 can manifest inflammation in organs other than the lung, in tissues not known to support viral replication, and also in a hypercoagulable state. These observations have suggested that severe acute respiratory syndrome coronavirus 2 can provoke a hyperimmune response in some cases that could lead to secondary organ damage. METHODS: With evidence of elevated levels of interleukin-6 (IL-6) in patients with severe COVID-19, we conducted a small pilot off-label compassionate care study of the IL-6 receptor inhibitor tocilizumab in patients with severe COVID-19. RESULTS: A single infusion of tocilizumab in patients with severe COVID-19 manifested rapid declines in C-reactive protein and d-dimer and gradual rises in lymphocyte and platelet counts. CONCLUSIONS: These findings suggest both pathophysiological mechanisms and clinical benefit that might be seen with IL-6 inhibition in severe COVID-19. Twit Text FOAVip Thromboinflammation response to tocilizumab in COVID-19 ????Res Pract Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=33043232 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33043232 #FOAvip English Wikipedia <ref>{{Cite pmid|33043232}}</ref> Thromboinflammation response to tocilizumab in COVID-19 #MMPMID33043232 Gergi M; Cushman M; Littenberg B; Budd RC Res Pract Thromb Haemost 2020[Nov]; 4 (8): 1262-1268 PMID33043232show ga BACKGROUND: Coronavirus disease-19 (COVID-19) spans a wide spectrum of illness. Severe cases of COVID-19 can manifest inflammation in organs other than the lung, in tissues not known to support viral replication, and also in a hypercoagulable state. These observations have suggested that severe acute respiratory syndrome coronavirus 2 can provoke a hyperimmune response in some cases that could lead to secondary organ damage. METHODS: With evidence of elevated levels of interleukin-6 (IL-6) in patients with severe COVID-19, we conducted a small pilot off-label compassionate care study of the IL-6 receptor inhibitor tocilizumab in patients with severe COVID-19. RESULTS: A single infusion of tocilizumab in patients with severe COVID-19 manifested rapid declines in C-reactive protein and d-dimer and gradual rises in lymphocyte and platelet counts. CONCLUSIONS: These findings suggest both pathophysiological mechanisms and clinical benefit that might be seen with IL-6 inhibition in severe COVID-19. äThromboinflammation response to tocilizumab in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing